Skip to content
Parker Institute for Cancer Immunotherapy
Search Close

Jingying Xu, PhD

Director, Regulatory Affairs

Translational and Regulatory


Jingying Xu, PhD, has broad scientific, clinical and regulatory experience in cancer immunotherapy. She joined PICI in April 2016, and has been playing a critical role in the clinical development of various projects as a clinical scientist. One of Xu’s primary focuses at PICI is to bring novel cellular and gene therapy from bench to bedside.

Prior to joining PICI, Xu was a key member with Stephen Forman’s CAR-T program at City of Hope and Jeff Bluestone’s Treg program at UCSF.

She received her PhD from the University of Southern California and her postdoctoral training at the University of California, Los Angeles.